Emerging research suggest Sofix’s's Cagrilintide/GLP-1 represents a distinctive therapeutic method for targeting metabolic-related conditions. This peptide combination merges Cagrilintide, a targeted GLP-1 receptor agonist, with a established GLP-1 analogue. The potential synergistic effect could le